Del Mastro Lucia, Clavarezza Matteo, Venturini Marco
Department of Medical Oncology, National Cancer Research Institute, L.go R. Benzi 10, 16132 Genoa, Italy.
Cancer Treat Rev. 2007 Dec;33(8):681-7. doi: 10.1016/j.ctrv.2007.07.014. Epub 2007 Sep 11.
Breast cancer continues to be one of the most prominent causes of cancer death among women worldwide. Mortality in breast cancer is most commonly caused by the occurrence of distant metastases. Thus, treatments that reduce the risk of distant metastases are likely to improve survival. The third-generation aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, have been investigated as alternatives to tamoxifen for the adjuvant treatment of early, endocrine-responsive breast cancer. Results from several large trials have established the superior efficacy of the AIs over tamoxifen in reducing the risk of recurrences when used as upfront, switch, and extended adjuvant therapy. Here, we review recent updated results obtained with AIs as adjuvant therapy, in terms of reducing the risk of distant metastases.
乳腺癌仍然是全球女性癌症死亡的最主要原因之一。乳腺癌的死亡率最常见的是由远处转移的发生所导致。因此，降低远处转移风险的治疗方法可能会提高生存率。包括阿那曲唑、来曲唑和依西美坦在内的第三代芳香化酶抑制剂（AIs）已被研究作为他莫昔芬的替代药物，用于早期内分泌反应性乳腺癌的辅助治疗。几项大型试验的结果已证实，当用作初始、转换和延长辅助治疗时，AIs在降低复发风险方面比他莫昔芬具有更高的疗效。在此，我们就降低远处转移风险方面，综述AIs作为辅助治疗所获得的最新结果。
